From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Wed, 26 Feb 2020 15:18:06 +0000

To: Cassetti, Cristina (NIH/NIAID) [E]

Subject: FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachments: NIAID EEEV -SP16_ Jan 28, 2020 - Read-Only - Read-Only.pdf, JACC manuscript

Oct 2017 SP16 AMI (1).pdf, Serpin Pharma - Non-Confidential Partnering Deck v29.pdf

Please take a look at this. Thanks.

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone:( £0) (6)
FAX: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. {t should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

  

From: Cohava Gelber ————— (6)
Sent: Tuesday, February 25, 2020 8:45 PM

To: Fauci, Anthony (NIH/NIAID) [E] fi —____—_—F
Subject: First in class, hemostatic drug - potential therapeutics for COVID-19
Importance: High

 

 

Dear Dr. Fauci,

NIH-001327
